Mirae Asset's 'TIGER BioTOP10 ETF' Tops Individual Cumulative Net Purchases

Mirae Asset Global Investments announced on the 20th that the ‘TIGER BioTOP10’ ranked first in cumulative net purchases by individuals among bio and healthcare sector exchange-traded funds (ETFs).

According to the Korea Exchange, as of the closing price on the 19th, the cumulative net purchase amount by individuals since the listing date of the ‘TIGER BioTOP10 ETF’ on October 7, 2020, is 93.5 billion KRW. There are a total of 20 ETFs in the bio and healthcare sector listed domestically. Among them, the most individual investor funds have flowed into this ETF.

The ‘TIGER BioTOP10 ETF’ is an ETF that focuses on leading domestic bio and healthcare stocks. As of the previous day, it holds 25% each in the domestic bio contract development and manufacturing organization (CDMO) leader ‘Samsung Biologics’ and the biosimilar leader ‘Celltrion.’ This is the highest investment ratio among ETFs listed domestically. Additionally, it invests 25% in ‘SK Biopharm.’

Recently, as domestic companies are expected to benefit from the global bio market, individual investors’ buying momentum for the ‘TIGER BioTOP10 ETF’ is strengthening. Currently, the U.S. government has shown willingness to open the biosimilar market to reduce drug prices. Furthermore, if sanctions against Chinese CDMO companies are imposed under the ‘Biosecurity Act’ being promoted by the U.S. Congress, domestic companies such as Samsung Biologics and Celltrion are expected to benefit. The Biosecurity Act is a bill that restricts transactions with bio companies designated by the U.S. Congress.

Shin Seung-woo, manager of the ETF Management Division at Mirae Asset Global Investments, said, “Looking at the sales growth trend in the healthcare sector this year, Samsung Biologics and Celltrion’s growth rates stand out clearly,” adding, “Through the ‘TIGER BioTOP10 ETF,’ investors can invest in K-bio companies active in the global bio market.”